多西他赛联合奥沙利铂卡培他滨治疗晚期胃癌的临床研究
刘丽英;陈小兵;高明
【期刊名称】《中国肿瘤临床》 【年(卷),期】2011(038)008
【摘要】Objective: To investigate the response rate and adverse reactions in patients with advanced or metastatic gastric cancer treated with the regimen of Docetaxel in combination with Oxaliplatin and Capecitabine.Methods: Fifty-six patients were treated with the regimen as follows: Docetaxel 75mg/m2, intravenous, day 1; Oxaliplatin 85mg/m2, intravenous, day 2; Capecitabine 1000mg/m2, twice a day, PO, for 14 days, 21 days for each cycle.Evaluation was performed at the end of 2 cyeles.Results: All of these 56 patients were evaluable for response.Six ( 10.7％ ) patients achieved complete response ( CR ), 30 ( 53.6％ ) patients had patial response ( PR ), 12 ( 21.4％ ) patients had stable disease ( SD ), 8 ( 14.3％ ) patients had disease progression ( DP ), with a total response rate (RR ) of 64.3％.The median progression-free survival was 6.2 months ( 3.6-11.8months ) and the median overall survival time was 11.6 months ( 5.9-14.6months ).The most common adverse effects were myelosuppression, gastrointestinal toxicities and neurotoxicity.No chemotherapy-related death was observed.Conclusion: Docetaxel combined with Oxaliplatin and Capecitabine is effective for advanced gastric cancer, with tolerable side effects.%目的:临床观察多西他
多西他赛联合奥沙利铂卡培他滨治疗晚期胃癌的临床研究
